Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102

NCT00606476 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT00606476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00606476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability, and Efficacy of Bapineuzumab (AAB-001) in Patients With Alzheimer's Disease Who Participated in Study AAB-001-201 or AAB-001-102
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2006
Completion date
September 30, 2012
Enrollment
194 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease